Ryo Hiramatsu

Osaka University of Pharmaceutical Sciences

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Shinji Kawabata

Osaka University of Pharmaceutical Sciences

Masahiko Wanibuchi

Osaka University of Pharmaceutical Sciences

Naosuke Nonoguchi

Osaka University of Pharmaceutical Sciences

Motomasa Furuse

Osaka University of Pharmaceutical Sciences

Ryokichi Yagi

Osaka University of Pharmaceutical Sciences

Toshihiko Kuroiwa

Osaka University of Pharmaceutical Sciences

Shin‐Ichi Miyatake

Osaka University of Pharmaceutical Sciences

Toshihiro Takami

Osaka University of Pharmaceutical Sciences

Hideki Kashiwagi

Osaka University of Pharmaceutical Sciences

Hiroki Tanaka

Kyoto University

Cooperative Institutions

Osaka Medical and Pharmaceutical University

Osaka University of Pharmaceutical Sciences

Kyoto University

Osaka University

Tohoku University

Toranomon Hospital

The University of Tokyo

Spintronics Research Network of Japan

Nagoya University

National Institute of Advanced Industrial Science and Technology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Corrigendum: Evaluation of the Effectiveness of the Tap Test by Combining the Use of Functional Gait Assessment and Global Rating of Change

Frontiers in Neurology (2022)

Masahiro Kameda Yoshinaga Kajimoto Yasutaka Nikaido Akihiro Kambara Kohei Tsujino

[This corrects the article DOI: 10.3389/fneur.2022.846429.].

10.3389/fneur.2022.926924

Cite

Citations (0)

Tetrakis(p-Carboranylthio-Tetrafluorophenyl)Chlorin (TPFC): Application for Photodynamic Therapy and Boron Neutron Capture Therapy

Journal of Pharmaceutical Sciences (2014)

Ryo Hiramatsu Shinji Kawabata Hiroki Tanaka Yoshinori Sakurai Minoru Suzuki

Chlorin

Neutron capture

10.1002/jps.24317

Cite

Citations (30)

Multi-Targeted Neutron Capture Therapy Combined with an 18 kDa Translocator Protein-Targeted Boron Compound Is an Effective Strategy in a Rat Brain Tumor Model

Cancers (2023)

Hideki Kashiwagi Yoshihide Hattori Shinji Kawabata Ryo Kayama Kohei Yoshimura

Boron neutron capture therapy (BNCT) has been adapted to high-grade gliomas (HG); however, some gliomas are refractory to BNCT using boronophenylalanine (BPA). In this study, the feasibility of BNCT targeting the 18 kDa translocator protein (TSPO) expressed in glioblastoma and surrounding environmental cells was investigated.Three rat glioma cell lines, an F98 rat glioma bearing brain tumor model, DPA-BSTPG which is a boron-10 compound targeting TSPO, BPA, and sodium borocaptate (BSH) were used. TSPO expression was evaluated in the F98 rat glioma model. Boron uptake was assessed in three rat glioma cell lines and in the F98 rat glioma model. In vitro and in vivo neutron irradiation experiments were performed.DPA-BSTPG was efficiently taken up in vitro. The brain tumor has 16-fold higher TSPO expressions than its brain tissue. The compound biological effectiveness value of DPA-BSTPG was 8.43 to F98 rat glioma cells. The boron concentration in the tumor using DPA-BSTPG convection-enhanced delivery (CED) administration was approximately twice as high as using BPA intravenous administration. BNCT using DPA-BSTPG has significant efficacy over the untreated group. BNCT using a combination of BPA and DPA-BSTPG gained significantly longer survival times than using BPA alone.DPA-BSTPG in combination with BPA may provide the multi-targeted neutron capture therapy against HG.

Translocator protein

10.3390/cancers15041034

Cite

Citations (7)

Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas – A Pilot Study

Neurologia medico-chirurgica (2018)

Hiroyuki Shiba Koji Takeuchi Ryo Hiramatsu Motomasa Furuse Naosuke Nonoguchi

Recurrent malignant gliomas (RMGs) are difficult to control, and no standard protocol has been established for their treatment. At our institute, we have often treated RMGs by tumor-selective particle radiation called boron neutron capture therapy (BNCT). However, despite the cell-selectivity of BNCT, brain radiation necrosis (BRN) may develop and cause severe neurological complications and sometimes death. This is partly due to the full-dose X-ray treatments usually given earlier in the treatment course. To overcome BRN following BNCT, recent studies have used bevacizumab (BV). We herein used extended BV treatment beginning just after BNCT to confer protection against or ameliorate BRN, and evaluated; the feasibility, efficacy, and BRN control of this combination treatment. Seven patients with RMGs (grade 3 and 4 cases) were treated with BNCT between June 2013 and May 2014, followed by successive BV treatments. They were followed-up to December 2017. Median overall survival (OS) and progression-free survival (PFS) after combination treatment were 15.1 and 5.4 months, respectively. In one case, uncontrollable brain edema occurred and ultimately led to death after BV was interrupted due to meningitis. In two other cases, symptomatic aggravation of BRN occurred after interruption of BV treatment. No BRN was observed during the observation period in the other cases. Common terminology criteria for adverse events grade 2 and 3 proteinuria occurred in two cases and necessitated the interruption of BV treatments. Boron neutron capture therapy followed by BV treatments well-prevented or well-controlled BRN with prolonged OS and acceptable incidence of adverse events in our patients with RMG.

10.2176/nmc.oa.2018-0111

Cite

Citations (20)

Proposal for quantifying the Dzyaloshinsky–Moriya interaction by domain walls annihilation measurement

Japanese Journal of Applied Physics (2014)

Ryo Hiramatsu Kab‐Jin Kim Y. Nakatani Takahiro Moriyama Teruo Ono

We show that the magnitude of the Dzyaloshinsky–Moriya interaction (DMI) can be determined by a field-driven domain-walls (DWs) annihilation measurement. It is predicted that the DMI induces antiparallel Néel DWs which form a metastable 360° DW when they approach to each other. We find that an annihilation field, over which two DWs collide and vanish, is proportional to the magnitude of the DMI. This result suggests that the DMI can be quantified by a simple measurement of the annihilation field.

Annihilation

Antiparallel (mathematics)

Metastability

10.7567/jjap.53.108001

Cite

Citations (14)

Stability of out-of-plane precession with the application of a tilted magnetic field in spin torque oscillator having a planar free layer and a perpendicular polarizer

The Japan Society of Applied Physics (2016)

Ryo Hiramatsu Hitoshi Kubota Sumito Tsunegi Shingo Tamaru Kay Yakushiji

Polarizer

Precession

Source

Cite

Citations (0)

Evaluation of the Effectiveness of the Tap Test by Combining the Use of Functional Gait Assessment and Global Rating of Change

Frontiers in Neurology (2022)

Masahiro Kameda Yoshinaga Kajimoto Yasutaka Nikaido Akihiro Kambara Kohei Tsujino

Although the tap test for patients with suspected idiopathic normal pressure hydrocephalus (iNPH) is still often performed as part of the preoperative evaluation, it is true that some studies have reported the limitations of the tap test, claiming that it does not provide the additional information for appropriate patient selection for surgery. We aimed to determine whether a better method of pre- and post-tap test assessment could lead to appropriate patient selection for shunting.We performed the tap test as part of the preoperative evaluation in all 40 patients who underwent lumboperitoneal shunt surgery for iNPH from April 2021 to September 2021. We retrospectively analyzed the patient data. We examined whether a comprehensive evaluation of the effect of the tap test using the Functional Gait Assessment (FGA) and Global Rating of Change (GRC) scales would identify a wider range of patients who would benefit from shunt surgery than the 3-m Timed Up and Go test (TUG) alone.Assuming a prevalence of 1% for iNPH, the TUG had a sensitivity of 0.23, specificity of 0.71, positive likelihood ratio of 0.79, and negative likelihood ratio of 1.09. When improvement in either the FGA or the GRC was used as a criterion for the validity of the tap test, the sensitivity was 0.88, specificity was 0.17, positive likelihood ratio was 1.06, and negative likelihood ratio was 0.71.Improvement in either the FGA or the GRC is a more sensitive criterion for the effectiveness of the tap test for the gait aspect than the TUG. Since the negative likelihood ratio is lower than that for the TUG alone, it is more appropriate to exclude patients with neither FGA nor GRC improvement from surgical indications than to exclude surgical indications based on a negative TUG.

10.3389/fneur.2022.846429

Cite

Citations (1)

The Therapeutic Effects of Dodecaborate Containing Boronophenylalanine for Boron Neutron Capture Therapy in a Rat Brain Tumor Model

Biology (2020)

Yusuke Fukuo Yoshihide Hattori Shinji Kawabata Hideki Kashiwagi Takuya Kanemitsu

Background: The development of effective boron compounds is a major area of research in the study of boron neutron capture therapy (BNCT). We created a novel boron compound, boronophenylalanine–amide alkyl dodecaborate (BADB), for application in BNCT and focused on elucidating how it affected a rat brain tumor model. Methods: The boron concentration of F98 rat glioma cells following exposure to boronophenylalanine (BPA) (which is currently being utilized clinically) and BADB was evaluated, and the biodistributions in F98 glioma-bearing rats were assessed. In neutron irradiation studies, the in vitro cytotoxicity of each boron compound and the in vivo corresponding therapeutic effect were evaluated in terms of survival time. Results: The survival fractions of the groups irradiated with BPA and BADB were not significantly different. BADB administered for 6 h after the termination of convection-enhanced delivery ensured the highest boron concentration in the tumor (45.8 μg B/g). The median survival time in the BADB in combination with BPA group showed a more significant prolongation of survival than that of the BPA group. Conclusion: BADB is a novel boron compound for BNCT that triggers a prolonged survival effect in patients receiving BNCT.

Neutron capture

10.3390/biology9120437

Cite

Citations (21)

Foramen magnum dural arteriovenous fistula treated by a microsurgical technique combined with a feeder occlusion using the transarterial coil embolization

Turkish Neurosurgery (2015)

Ryo Hiramatsu Terumasa Kuroiwa Kazuhiko Nozaki Toshihiko Kuroiwa

The treatment of dural arteriovenous fistulas (DAVFs) at the foramen magnum remains controversial by reason that DAVFs appearing from the foramen magnum represent only a minority of spinal DAVFs. We present our treatment for an asymptomatic patient suffering from a foramen magnum DAVF. A 53-year-old man presented to our hospital with the complaint of a floating sensation. Although there was no subarachnoid hemorrhage or cerebral infarction on magnetic resonance imaging, a magnetic resonance angiography revealed a number of dilated veins and a large varix surrounding the medulla oblongata. Cerebral digital subtraction angiography (DSA) showed a foramen magnum DAVF fed by the neuromeningeal branch of the left ascending pharyngeal artery and occipital artery, draining into the posterior spinal vein. Occlusion of the fistula was achieved by a microsurgical technique combined with a feeder occlusion using transarterial coil embolization, without complications. We verified the complete occlusion on post-operative cerebral DSA. While this combined therapy was already established for the treatment of DAVFs, there were no reports of the combined therapy for foramen magnum DAVFs. This treatment was considered to be useful for foramen magnum DAVFs, especially those DAVFs at the foramen magnum with a number of dilated veins and a large varix.

Foramen magnum

10.5137/1019-5149.jtn.11860-14.3

Cite

Citations (9)

Nonclinical pharmacodynamics of boron neutron capture therapy using direct intratumoral administration of a folate receptor targeting novel boron carrier

Neuro-Oncology Advances (2024)

Kohei Tsujino Hideki Kashiwagi Kai Nishimura Yoshiki Fujikawa Ryo Kayama

Boron neutron capture therapy (BNCT) is a precise particle radiation therapy known for its unique cellular targeting ability. The development of innovative boron carriers is crucial for the advancement of BNCT technologies. Our previous study demonstrated the potential of PBC-IP administered via convection-enhanced delivery (CED) in an F98 rat glioma model. This approach significantly extended rat survival in neutron irradiation experiments, with half achieving long-term survival, akin to a cure, in a rat brain tumor model. Our commitment to clinical applicability has spurred additional nonclinical pharmacodynamic research, including an investigation into the effects of cannula position and the time elapsed post-CED administration.

Folate receptor

Pharmacodynamics

Neutron capture

10.1093/noajnl/vdae062

Cite

Citations (2)